Show simple item record

dc.contributor.authorArababadi, Mohammad Kazemi
dc.contributor.authorMosavi, Reza
dc.contributor.authorKhorramdelazad, Hossein
dc.contributor.authorYaghini, Narges
dc.contributor.authorZarandi, Ebrahim Rezazadeh
dc.contributor.authorAraste, Majid
dc.contributor.authorPourali, Reza
dc.contributor.authorNekhei, Zohre
dc.contributor.authorKennedy, Derek
dc.date.accessioned2017-05-03T11:12:28Z
dc.date.available2017-05-03T11:12:28Z
dc.date.issued2010
dc.date.modified2011-10-06T04:59:12Z
dc.identifier.issn1752-0363
dc.identifier.doi10.2217/BMM.10.81
dc.identifier.urihttp://hdl.handle.net/10072/34904
dc.description.abstractBackground and aim: Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This project aimed to evaluate the serum levels of relevant cytokines after therapy with IFN-? formulations in MS patients. Material and methods: In this study, blood samples were collected from 70 MS patients undergoing four different types of IFN-? formulation treatment and 100 healthy controls. After 24 months of treatment the serum levels of IL-17A, IL-12 and IFN-g and IL-10 in patients and healthy controls were analyzed by ELISA. Finding: Our results showed that serum levels of IL-17A were significantly higher in patients treated with Cinnovex and Anovex when compared to healthy controls. Serum levels of IL-10 were significantly decreased after therapy with Cinnovex, whereas serum levels of IFN-? were elevated. No difference in serum levels of IL-12 were detected in patients and controls. Conclusion: Results of our study suggest that Cinnovex and Anovex modulate the immune system less than Rebif and Betaferon in MS patients and that an elevated dosage/regime of Cinnovex and Anovex may be required for better regulation of the immune system in MS patients.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent90805 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_AU
dc.publisherFuture Medicine
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom755
dc.relation.ispartofpageto759
dc.relation.ispartofissue5
dc.relation.ispartofjournalBiomarkers in Medicine
dc.relation.ispartofvolume4
dc.rights.retentionY
dc.subject.fieldofresearchMedical Genetics (excl. Cancer Genetics)
dc.subject.fieldofresearchMedicinal and Biomolecular Chemistry
dc.subject.fieldofresearchMedical Biochemistry and Metabolomics
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchcode110311
dc.subject.fieldofresearchcode0304
dc.subject.fieldofresearchcode1101
dc.subject.fieldofresearchcode1103
dc.titleCytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing–remitting multiple sclerosis in Iranian patients
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.rights.copyright© 2010 Future Medicine Ltd. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal website for access to the definitive, published version.
gro.date.issued2010
gro.hasfulltextFull Text
gro.griffith.authorKennedy, Derek D.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record